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Background: Overwintering (breeding) reindeer (Rangifer tarandus tarandus) are commonly treated with ivermectin
against parasitic infestations once yearly in autumn-winter roundups. The only preparations registered to reindeer
are those for subcutaneous injection. However, also oral extra-label ivermectin administration is used. Twenty-six,
8-month-old reindeer calves were randomly allocated into three groups. Group 1 (n = 9) received oral ivermectin
mixture (Ivomec® vet mixt. 0.8 mg/ml, oral ovine liquid drench formulation), Group 2 (n = 9) oral ivermectin paste
(Ivomec® vet 18.7 mg/g equine paste), and Group 3 (n = 8) subcutaneous injection of ivermectin (Ivomec®
10 mg/ml vet inj.), each group at a dose of 200 μg/kg body weight. Blood samples were collected at treatment and
at days 1, 2, 3, 6, 9 and 16 post treatment. Plasma concentrations of ivermectin were determined by high-pressure
liquid chromatography (HPLC) with fluorescence detection.
Results: The peak plasma concentration (Cmax) was reached by 2 days after each treatment. The Cmax and Area
Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml,
and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ±
standard deviation).
Conclusions: The differences in plasma concentrations of ivermectin are concomitant with earlier observed
differences in antiparasitic efficacy, which discounts the use of the equine paste in reindeer in favour of the oral
ovine liquid drench formulation, or preferably, the reindeer-registered subcutaneous injection formulation.
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Since the launch at the production animal market, iver-
mectin has been widely used to treat different endo-
parasite and ectoparasite (nematodes and arthropods)
infections in the main production animal species [1],
and also in “minor” ruminant species such as goats, deer,
buffaloes, antelopes, and also camelids. In a review of
extra-label use in minor species [2], it was concluded
that there is a high inter-species variability in ivermectin* Correspondence: Antti.Oksanen@evira.fi
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unless otherwise stated.pharmacokinetics and efficacy and a need for extended
pharmacokinetic data in various animal species to avoid
misuse of dose rates extrapolated from other species.
Ivermectin has been used to treat both arthropod
and nematode parasites of reindeer (Rangifer tarandus
tarandus) since the early 1980s [3,4] with as many as
80% of the overwintering reindeer in Finland treated once
yearly [5]. The only ivermectin preparation registered for
administration to reindeer in any Fennoscandian country
is injectable (e.g. Ivomec® 10 mg/ml vet inj., Merial), at
200 μg/kg subcutaneously (s.c.). The equine oral paste
(Ivomec® vet 18.7 mg/g paste, Merial) is not intended byal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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adopted to the treatment of reindeer in Finland after rein-
deer herders had seen that administration at 200 μg/kg
had high efficacy against reindeer warbles (Hypoderma
tarandi) and throat bots (Cephenemyia trompe), which
effect was later demonstrated experimentally [6]. The
oral ovine liquid drench formulation (Ivomec® vet mixt.,
0.8 mg/ml, Merial) is occasionally used on reindeer in
Norway (Aamot, Herdis G., pers. comm., 2013). This
study compares the plasma concentrations of ivermectin
in reindeer after administration of the oral ovine liquid
drench and equine paste formulations, and the subcuta-
neous injection, and discusses the consequences of the
observed differences to antiparasitic effect and resistance.
Material and methods
Twenty-six (13 females and 13 males) individually ear-
tagged 8-month-old reindeer calves of the Kaamanen Ex-
perimental Reindeer Herd, Kaamanen, Finnish Lapland,
were corralled at the Finnish Game and Fisheries Research
Institute’s Reindeer Research Station animal experiment
facilities and fed lichen and commercial reindeer feed
pellets (Poron-Herkku, Rehu-Raisio, Finland) ad lib. The
animals were weighed (median body weight 46 kg, range
42 to 53 kg) and allocated by sex and weight into three
treatment groups: 1) ovine Ivomec® vet mixt. 0.8 mg/ml,
n = 9; 2) equine Ivomec® vet 18.7 mg/g paste, n = 9; and 3)
Ivomec® 10 mg/ml vet inj., n = 8. The treatments were
performed after pelleted fodder had been added to their
feed troughs in the morning. All animals were dosed at
200 μg/kg body weight. Those in Groups 1 and 2 were
treated by emptying an individually filled syringe on the
base of the tongue, 0.25 ml/kg and 10.7 mg/kg, respect-
ively. Subcutaneous injections (Group 3) were given in
front of the left shoulder (lateral midline of the neck) at
0.02 ml/kg. Blood samples were collected into evacuated
sodium heparinised 10 ml tubes (Venoject) immediately
prior to treatment (day 0) and at the same time of day on
days 1, 2, 3, 6, 9 and 16 post treatment. Plasma was sepa-
rated by centrifugation, stored at -20°C, and only thawed
once for analysis.
The experiment was performed with the permission
from Finnish Game and Fisheries Research Institute’s
Animal Care Committee.
Ivermectin concentration in plasma was determined
by high-pressure liquid chromatography (HPLC) with
fluorescence detection following a modification of the
method described for ivermectin in reindeer faeces
[7,8]. The modifications included that the 1.0 ml plasma
sample was supplemented with 10 ng of abamectin in-
ternal standard, mixed with 5 ml of 30% acetone, and
the iso-octane extraction step was performed with 5 ml
portions of iso-octane. A single calibration line based on
the least-squares method was used for the quantificationof ivermectin. Concentrations were calculated according
to the equation:





where Cs is the plasma concentration (ng/ml); Rf1 and
Rf2 are the response factors representing the calibration
line used, 1.1777 and 0, respectively; Hi and Ha are the
HPLC software-generated heights of the ivermectin B1a
and abamectin Bla peaks, respectively; Wa is the internal
standard weight (ng); Ws, the sample volume (ml); Df, the
dilution factor for sample injected. For recovery calculation,
1.0 ml plasma portions from untreated animals fortified
with concentrations of ivermectin ranging from 1 to
100 ng/ml were analysed, and recovery was calculated
according to equation published before [7].
The plasma ivermectin concentration-time profiles were
examined using WinNonLin 6.3 (Statistical Consulting
Inc. Pharsight Corporation, Cary, NC, USA) software with
non-compartmental analysis, linear trapezoidal linear/log
interpolation, uniform weighting. Appropriate basic phar-
macokinetic parameters, mean and standard deviation,
were generated. For calculation, the first ivermectin con-
centration from an animal below the level that could be
recovered and determined (1 ng/ml) was replaced with
0.5 ng/ml. The relative plasma availability of ivermectin
(Frel) was approximated by using the mean AUCs of each
group and calculating (AUCoral/AUCsc)*100%, where s.c.
route was used as a reference. Differences in maximum
concentration (Cmax) and Area Under the plasma ivermec-
tin concentration-time Curve (AUC∞) between treatments
were analyzed with analysis of variances by JMP statistical
software (ver. 11, SAS Institute Inc., www.jmp.com). The
null hypothesis was rejected at an α-level of 0.05.
Results
Chromatography of 1.0 ml plasma samples from an
untreated reindeer fortified with various amounts of
ivermectin demonstrated that fortification levels down to
1 ng/ml could easily be detected and measured by HPLC.
Retention times for the Bla components of abamectin and
ivermectin were approximately 5.1 and 7.5 min, respect-
ively, with the Blb components eluting a little less than
1 min earlier (Figure 1). The individual peaks were well re-
solved at all fortification levels, and no extraneous peaks in-
terfered with the Bla components, as demonstrated by
analysis of non-fortified plasma from untreated animals.
The relative recovery rate ranged from ~99 to ~116% for
the whole concentration range (1-100 ng/ml), and reproduc-
ibility was good (standard deviation less than 5.2% for con-
centration determined for 5 identically prepared samples).
One animal of Group 3 gave analysis results showing
complete absence of ivermectin in all samples and was
Figure 1 An example HPLC chromatogram for an actual plasma sample from a reindeer treated with ivermectin by oral administration
of equine paste (Group 2) at the dose of 200 μg/kg. Sample from day 2 post treatment, concentration determined to 9 ng/ml. HPLC detector
attenuation: 3. Each plasma sample for analysis (1.0 ml) was supplemented with 10 ng abamectin (internal standard) before extraction and sample
preparation. The plasma concentration calculation was based on the HPLC software-generated heights of the ivermectin B1a and abamectin Bla peaks
using the equation given above.
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samples of other animals, 17 were missing from analysis
for various reasons.
Mean plasma ivermectin concentrations by time post
treatment for each group are shown in Figure 2. The ma-
ximum measured ivermectin concentration (Cmax) wasFigure 2 Mean (+ standard deviation) plasma ivermectin concentratio
(x-axis: days after treatment), 1) broken line, Ivomec® vet mixt. 0.8 mg
orally n = 9; 3) solid line, Ivomec® 10 mg/ml vet inj. subcutaneously nreached by day 2 post treatment (Tmax). One animal in
Group 2 exhibited an exceptionally high plasma ivermec-
tin concentration on day 1 (29 ng/ml, compared to the
mean of 11.8 ng/ml for the other eight of the group) and
caused the mean concentration in that group in Figure 2
to peak on day 1 (mean = 13.7, day 2 mean = 12.2 ng/ml).n (ng/ml) in three groups of reindeer treated with ivermectin
/ml orally n = 9; 2) dotted line, Ivomec® vet 18.7 mg/g paste
= 8. All treatments at a dose of 200 μg/kg.
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groups (Table 1), and the mean Cmax and AUC were
significantly lower for Group 2 compared to Groups 1 and
3, and significantly higher for Group 3 compared to
Groups 1 and 2 (one way ANOVA, Tukey test, P < 0.007).
No ivermectin could be detected on day 16 post treatment
in any animal indicating that the plasma concentrations
were below the detection limit (1 ng/ml). The approxi-
mated Frel were 43% and 19% for the oral mixture and
paste, respectively.
Discussion
The maximum ivermectin plasma concentrations mea-
sured in the subcutaneously injected reindeer were higher
in this study than in a previous one with similar animals
[9]. In that earlier experiment, no sampling was done on
day 2 after treatment, but only on days 1 and 3, and thus
Cmax was probably missed. Otherwise, the results from
these two experiments were similar, suggesting the supe-
rior plasma availability of ivermectin after subcutaneous
injection compared to oral administration. Maybe Cmax
were not seen in the current study either, because they
may be anywhere between days 1 and 2, or between days
2 and 3. The Tmax of ivermectin in reindeer is in any case
longer than in some other cervid species where it has been
less than 1 day (see below) but shorter than or similar
to cattle, sheep and goats (reviewed in [2]). The Cmax
following subcutaneous administration at 200 μg/kg
was considerably higher in our study than observed in
cattle [10-12].
It is most interesting to compare the findings with re-
sults from other cervid species. After s.c. injection of
ivermectin in red deer (Cervus elaphus) at 200 μg/kg,
Cmax was only 15.8 ng/ml [13], about one fourth of that
measured in the current study. In red deer the Tmax
was 20 hours. Similar values were obtained in another
study in red deer [14]. In white-tailed deer (Odocoileus
virginianus) sampled days 3, 7, 14, and 21 post injection,
Cmax was observed in the first sampling, on day 3 postTable 1 Basic pharmacokinetic parameters of ivermectin
administered orally (as mixture or paste), or








Tmax (days) 2 1 2
Cmax (ng/ml) 30.2 ± 3.9
a 14.9 ± 5.7b 63.1 ± 13.1c
AUC∞ (ng*h/ml) 2881 ± 462
a 1299 ± 342b 6718 ± 1620c
Frel 0.43 0.19 1
Means of the groups marked with different letters (a, b, c) differ significantly
(P < 0.05).injection; the serum concentration was about 30 ng/ml, al-
most double the Cmax in red deer [15]. The elimination to
non-detectable serum concentration (<2 ppb ~ 2 ng/ml)
lasted not more than 21 days after injection [15]. However,
these findings are not fully comparable, as the sampling
intervals differed between studies and the peak concen-
trations may not have been measured due to infrequent
sampling. In fallow deer (Cervus dama dama), injectable
abamectin (200 μg/kg, s.c.), chemically a closely related
and pharmacologically rather similar drug, produced a
Cmax of 120 ng/ml at 19 h post injection [16]. In spite of
the similarities, ivermectin is regarded as the least lipo-
philic of the macrocyclic lactone antiparasitics [17], which
probably causes differences between the pharmacokinetics
of these two compounds. As stated [2], erroneous dosages
may emerge when extrapolating recommended treatments
from one animal species to another. This appears very
clearly evident also within the Cervidae family.
In the present study, the elimination half-time and mean
residence time could not be calculated accurately, as the
slow absorption was probably a limiting factor for the
elimination causing the so called flip-flop pharmacoki-
netics. Thus the main, and clinically most important,
differences between the groups were in Cmax and AUC.
Plasma concentration, or specifically AUC, of a macrocyc-
lic lactone in a given animal species has been suggested to
indicate the level of antiparasitic efficacy [18]. It was
suggested that there may be a minimum plasma drug
concentration (between 0.5 and 1 ng/ml [19] for optimal
anthelmintic activity against susceptible gastrointestinal or
lung nematodes. However, the existence of such a mini-
mum effective concentration has not been confirmed. In
any case, the efficacy concentration and duration require-
ments are affected by physiological and biochemical dif-
ferences between both host and parasite species and
strains.
Even though more sensitive analytical methods do exist
[20], we consider our method appropriate for the focus of
the present work, the comparison between the practical
outcomes of the three administration regimes in question,
particularly when laboratory cost-effectiveness and labour-
intensity also are taken into account. An important
problem with the relatively low analytical sensitivity of the
method is that it was not possible to detect the prolonged
low concentrations which may be important in anthelmin-
tic resistance build-up in nematode populations. Further-
more, the elimination parameters could not be calculated.
The efficacy of ivermectin formulations against gastro-
intestinal trichostrongylid nematodes in reindeer has been
assessed in several previous studies based on the reduction
in faecal egg output in the Kaamanen Herd. The s.c. injec-
tion treatment reduced the faecal egg count mean (based
on several repeated samplings of individual animals 2 to
6 months post treatment) by 80-95% [21,22]; the equine
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[23]. These efficacy figures were consistent both with the
Cmax and AUC differences detected in the present study.
Based on Cmax and AUC comparisons between the dif-
ferent preparations and administrations, the equine iver-
mectin paste may have similar antiparasitic efficacy, at
least against extra-intestinal parasites, to a lower dose of
the ovine mixture, or to an even lower dose injected sub-
cutaneously, which low injection dose would naturally be
regarded as evident underdosage.
The reason for the obviously better absorption to the
circulation of ivermectin from the ovine mixture com-
pared to the equine paste may be in the chemical com-
position of the base material of the products, but one
possible explanation is in the consistence and volume of
the drench. The equine paste dose containing 200 μg/kg
of ivermectin and given to a 50 kg reindeer calf is
0.535 g of viscous paste, while that of the ovine mixture
is 12.5 ml of liquid. If some of the mixture bypasses the
rumen to end up directly in the abomasum, the absorp-
tion to the body might be greatly enhanced. In an early
study in sheep, the bioavailability of intra-abomasally
administered ivermectin was 100%, while that of iver-
mectin administered intraruminally was only 25% [24].
It was suggested that orally administered ivermectin is
adsorbed to the ruminal ingesta [24,25], which limits its
availability for absorption. Accordingly, also the systemic
availability of intraruminally administered doramectin in
sheep is low, 35% [26]. In our study, the approximated
relative plasma availability was lower for the paste and
higher for the mixture in reindeer than these values re-
ported for intraruminal administration in sheep [24].
Ruminal bypass could be explained by the oesophageal
groove closure directing the drug mixture directly to the
abomasum. This explanation loses some credibility be-
cause ruminal bypass was found not to take place in
adult reindeer [27]. The 8-month-old reindeer calves in
the present study had recently been weaned; the end of
lactation takes place typically 24 to 26 weeks after birth
[28]. Possibly the animals’ raised head posture during
administration anyhow directs ivermectin mixture to the
abomasum. It can also be difficult to make sure that the
reindeer swallow the small volume of paste. In this study,
proper restraint of the animals ensured swallowing.
We are not aware of any reports of macrocyclic
lactone resistance in any oestrid fly species, such as
reindeer warble and throat bot flies, but resistance in
gastrointestinal nematode parasites is a major problem
in many areas where e.g. sheep are intensively treated
[29,30]. We do not know of any report of ivermectin re-
sistance in any reindeer parasites. However, after two de-
cades of moxidectin pour-on use on a New Zealand deer
farm, significant resistance to moxidectin and abamectin
in abomasal nematodes was seen [31]. Moxidectin isapparently not used in reindeer, as it was found not to
have satisfactory efficacy against the important insect
parasites, warbles and throat bots [22]. Pour-on ivermec-
tin preparation was found to have very low absorption
into the reindeer body, especially in midwinter [9].
As underdosage is regarded as a driver of resistance
[32], it should definitely be avoided. On the other hand,
persistent activity of macrocyclic lactones creates situa-
tions in which treated animals have prolonged low con-
centration of the drug in the body, which may allow (re)
infection by the fittest of parasite larvae [33]. From that
point of view, rapid disappearance of the drug would be
preferable, and there oral administrations probably
score highest. Ivermectin is mostly excreted unaltered
in the faeces [34], and the environmental contamination
[8] will be similar in size, but not in time, regardless the
application route.
However, systemic plasma availability is probably not
essential as a measure of antiparasitic activity; it is the
availability of the toxic substance to the parasites that
really counts. While plasma concentration virtually cer-
tainly determines the availability of ivermectin to paren-
teral nematodes (such as e.g. Dictyocaulus eckerti, Setaria
tundra and Rumenfilaria andersoni) and warble and
throat bot fly larvae, the situation regarding gastrointes-
tinal nematodes is somewhat confusing. In recent studies
in sheep and cattle, oral macrocyclic lactones have been
shown to have higher efficacy against gastrointestinal
nematodes than subcutaneous injection [35,36], even
against Haemonchus contortus, which is known to feed on
blood. One probable explanation to the observed difference
in effect against reindeer abomasal nematodes (Ostertagia
gruehneri) [37] and those of sheep and cattle, is that during
the time of treatment, reindeer nematodes mostly reside in
the abomasal mucosa as inhibited larvae [37,38], and
cannot get in contact with drug in ingesta; thus, ivermectin
is only available to them via blood circulation.Conclusions
This study has defined the plasma concentrations of
ivermectin in reindeer using three formulations, and the
results agree well with previously acquired anthelmintic
efficacy data. With this information, some directions for
the best use of drug can be made. Specifically, if an injec-
tion is impractical to administer e.g. due to lack of capable
personnell, and ivermectin treatment is still required, the
higher relative plasma availability of ivermectin in the
mixture formulation, designed to be used in a ruminant
species, suggests that it would be a better substitute than
the paste designed for a monogastric species.Competing interests
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